

Gaia Colombo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1932427/publications.pdf>

Version: 2024-02-01

67
papers

2,983
citations

159358
30
h-index

168136
53
g-index

72
all docs

72
docs citations

72
times ranked

3884
citing authors

#	ARTICLE	IF	CITATIONS
1	Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma. <i>Pharmaceutics</i> , 2021, 13, 362.	2.0	3
2	Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120827.	2.6	9
3	Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs. <i>Molecular Pharmaceutics</i> , 2021, 18, 3132-3146.	2.3	37
4	Nasal powders of quercetin- β -cyclodextrin derivatives complexes with mannitol/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation. <i>International Journal of Pharmaceutics</i> , 2021, 607, 121016.	2.6	27
5	Inhalable Microparticles Embedding Calcium Phosphate Nanoparticles for Heart Targeting: The Formulation Experimental Design. <i>Pharmaceutics</i> , 2021, 13, 1825.	2.0	13
6	Preparation and Biophysical Characterization of Quercetin Inclusion Complexes with β -Cyclodextrin Derivatives to be Formulated as Possible Nose-to-Brain Quercetin Delivery Systems. <i>Molecular Pharmaceutics</i> , 2020, 17, 4241-4255.	2.3	35
7	Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats. <i>Journal of Controlled Release</i> , 2020, 323, 412-420.	4.8	21
8	Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction. <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 1664-1673.	0.9	8
9	Aerosolization Performance of Jet Nebulizers and Biopharmaceutical Aspects. <i>Pharmaceutics</i> , 2019, 11, 406.	2.0	18
10	Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease. <i>Journal of Drug Targeting</i> , 2019, 27, 984-994.	2.1	21
11	Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery. <i>International Journal of Biological Macromolecules</i> , 2019, 129, 267-280.	3.6	78
12	Chitosan-Coated Nanoparticles: Effect of Chitosan Molecular Weight on Nasal Transmucosal Delivery. <i>Pharmaceutics</i> , 2019, 11, 86.	2.0	79
13	The use of fatty acids as absorption enhancer for pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2018, 541, 93-100.	2.6	19
14	<i>In vivo</i> nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. <i>Drug Delivery</i> , 2018, 25, 376-387.	2.5	54
15	Opportunity and challenges of nasal powders: Drug formulation and delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 113, 2-17.	1.9	83
16	Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 113, 18-28.	1.9	46
17	Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. <i>Pharmaceutics</i> , 2018, 10, 34.	2.0	206
18	Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. <i>International Journal of Pharmaceutics</i> , 2018, 548, 182-191.	2.6	27

#	ARTICLE	IF	CITATIONS
19	Design of experiments (DoE) in pharmaceutical development. Drug Development and Industrial Pharmacy, 2017, 43, 889-901.	0.9	298
20	Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect. Journal of Controlled Release, 2017, 262, 296-304.	4.8	10
21	The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis. International Journal of Pharmaceutics, 2016, 514, 392-398.	2.6	19
22	Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. International Journal of Pharmaceutics, 2016, 514, 229-237.	2.6	22
23	Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antiseecretory activity in conscious rats. Journal of Controlled Release, 2016, 239, 203-210.	4.8	12
24	Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. International Journal of Pharmaceutics, 2016, 502, 242-248.	2.6	19
25	From tablets to pharmaceutical nanotechnologies: Innovation in drug delivery strategies for the administration of antimalarial drugs. Journal of Drug Delivery Science and Technology, 2016, 32, 167-173.	1.4	13
26	Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. Drug Development and Industrial Pharmacy, 2016, 42, 332-339.	0.9	23
27	Ex vivo permeation of tamoxifen and its 4-OH metabolite through rat intestine from lecithin/chitosan nanoparticles. International Journal of Pharmaceutics, 2015, 491, 99-104.	2.6	49
28	Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 165-172.	2.0	46
29	Immunomodulatory Effects of a Low-Dose Clarithromycin-Based Macrolide Solution Pressurised Metered Dose Inhaler. Pharmaceutical Research, 2015, 32, 2144-2153.	1.7	13
30	High shear mixing of lactose and salmeterol xinafoate dry powder blends: Biopharmaceutic and aerodynamic performances. Journal of Drug Delivery Science and Technology, 2015, 30, 443-449.	1.4	13
31	The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. Journal of Pharmacy and Pharmacology, 2014, 66, 639-645.	1.2	11
32	Multicomponent antibiotic substances produced by fermentation: Implications for regulatory authorities, critically ill patients and generics. International Journal of Antimicrobial Agents, 2014, 43, 1-6.	1.1	42
33	Spray dried amikacin powder for inhalation in cystic fibrosis patients: A quality by design approach for product construction. International Journal of Pharmaceutics, 2014, 471, 507-515.	2.6	44
34	Pure insulin highly respirable powders for inhalation. European Journal of Pharmaceutical Sciences, 2014, 51, 110-117.	1.9	30
35	Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems. Current Topics in Medicinal Chemistry, 2014, 14, 1182-1193.	1.0	37
36	Agglomerated Oral Dosage Forms of Artemisinin/ β -2-Cyclodextrin Spray-Dried Primary Microparticles Showing Increased Dissolution Rate and Bioavailability. AAPS PharmSciTech, 2013, 14, 911-918.	1.5	22

#	ARTICLE	IF	CITATIONS
37	Production of polymeric micelles by microfluidic technology for combined drug delivery: Application to osteogenic differentiation of human periodontal ligament mesenchymal stem cells (hPDLSCs). International Journal of Pharmaceutics, 2013, 440, 195-206.	2.6	35
38	Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration. International Journal of Pharmaceutics, 2013, 451, 50-56.	2.6	4
39	Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats. International Journal of Pharmaceutics, 2013, 440, 154-160.	2.6	21
40	Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: Loading, enzyme-trigger release and cell uptake. Journal of Controlled Release, 2013, 167, 276-283.	4.8	55
41	Treatment of equine sarcoids. Veterinary Record, 2012, 171, 330-330.	0.2	4
42	Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. International Journal of Pharmaceutics, 2012, 426, 100-107.	2.6	80
43	Particles and powders: Tools of innovation for non-invasive drug administration. Journal of Controlled Release, 2012, 161, 693-702.	4.8	59
44	Assemblage of drug release modules: Effect of module shape and position in the assembled systems on floating behavior and release rate. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 116-121.	2.0	17
45	Geometric Release Systems: Principles, Release Mechanisms, Kinetics, Polymer Science, and Release-Modifying Material. , 2011, , 221-237.		2
46	Layered lipid microcapsules for mesalazine delayed-release in children. International Journal of Pharmaceutics, 2011, 421, 293-300.	2.6	20
47	Brain distribution of ribavirin after intranasal administration. Antiviral Research, 2011, 92, 408-414.	1.9	68
48	Pectin Matrix as Oral Drug Delivery Vehicle for Colon Cancer Treatment. AAPS PharmSciTech, 2011, 12, 201-214.	1.5	166
49	Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products. Journal of Controlled Release, 2010, 146, 54-60.	4.8	17
50	In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: The enhancing effect of potassium sorbate. European Journal of Pharmaceutical Sciences, 2009, 37, 36-42.	1.9	32
51	Novel Platforms for Oral Drug Delivery. Pharmaceutical Research, 2009, 26, 601-611.	1.7	92
52	Therapeutic Paint of Cidofovir/Sucralfate Gel Combination Topically Administered by Spraying for Treatment of orf virus Infections. AAPS Journal, 2009, 11, 242-249.	2.2	18
53	Brain uptake of an anti-ischemic agent by nasal administration of microparticles. Journal of Pharmaceutical Sciences, 2008, 97, 4889-4903.	1.6	62
54	Methacholine dry powder inhaler as a new tool for bronchial challenge test. International Journal of Pharmaceutics, 2008, 352, 165-171.	2.6	11

#	ARTICLE	IF	CITATIONS
55	Module assemblage technology for floating systems: In vitro flotation and in vivo gastro-retention. Journal of Controlled Release, 2008, 129, 88-92.	4.8	34
56	The effect of residual water on antacid properties of sucralfate gel dried by microwaves. AAPS PharmSciTech, 2006, 7, E58-E63.	1.5	10
57	Assemblage of novel release modules for the development of adaptable drug delivery systems. Journal of Controlled Release, 2006, 111, 212-218.	4.8	50
58	Mechanisms of formation and disintegration of alginate beads obtained by prilling. International Journal of Pharmaceutics, 2005, 302, 1-9.	2.6	124
59	Prolonged duration local anesthesia with lipid-protein-sugar particles containing bupivacaine and dexamethasone. Journal of Biomedical Materials Research - Part A, 2005, 75A, 458-464.	2.1	54
60	Effect of Residual Water Content on the Physico-Chemical Properties of Sucralfate Dried Gel Obtained by Microwave Drying. Drug Development and Industrial Pharmacy, 2005, 31, 645-652.	0.9	3
61	Effect of excipient composition on the biocompatibility of bupivacaine-containing microparticles at the sciatic nerve. Journal of Biomedical Materials Research Part B, 2004, 68A, 651-659.	3.0	22
62	Prolongation of sciatic nerve blockade by in situ cross-linked hyaluronic acid. Biomaterials, 2004, 25, 4797-4804.	5.7	170
63	Bioadhesive film for the transdermal delivery of lidocaine: in vitro and in vivo behavior. Journal of Controlled Release, 2003, 88, 277-285.	4.8	99
64	Post-iontophoresis transport of ibuprofen lysine across rabbit ear skin. International Journal of Pharmaceutics, 2003, 266, 69-75.	2.6	13
65	In vitro and in vivo Study of 5-Methoxypsoralen Skin Concentration after Topical Application. Skin Pharmacology and Physiology, 2003, 16, 130-136.	1.1	11
66	Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheres. Pain, 2003, 104, 415-421.	2.0	110
67	Skin Permeation of 5-Methoxypsoralen from Topical Dosage Forms. Drug Development and Industrial Pharmacy, 2003, 29, 247-251.	0.9	2